Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
4SCAR-T Therapy Targeting GD2, PSMA and CD276 for Neuroblastoma
NCT04637503Phase 2Not yet recruiting
- Sponsor
- Shenzhen Geno-Immune Medical Institute
- Start
- Dec 2026
- Primary completion
- Dec 2029
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of GD2 CAR-T cells + PSMA CAR-T cells + CD276 CAR-T cells in neuroblastoma, sponsored by Shenzhen Geno-Immune Medical Institute. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
GD2 CAR-T cells + PSMA CAR-T cells + CD276 CAR-T cells
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on NCT04637503.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04637503.